Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib in HER2+ Early Breast Cancer After Adjuvant Trastuzumab
NCT03980054Phase 3Active, not recruiting
- Sponsor
- Hengrui
- Start
- Jul 2019
- Primary completion
- Jun 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Arm Pyrotinib with Arm Placebo (2 arms). Primary endpoint: Invasive Disease-free Survival at 2 years. Started Jul 2019; status: active, not recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03980054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03980054.